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fracture, vertebral fracture, breast cancer, colorectal cancer, ovarian cancer, coro-
nary heart disease, stroke and venous thromboembolic events. Health states were 
mutually exclusive. Women were followed through a VMS phase and an additional 
post-VMS phase in order to assess the treatment effects on the LTEs, representing a 
life-time horizon. Women were assumed to experience VMS and receive treatment 
for 4 years, additionally, onset of vaginal bleeding or any LTE resulted in treatment 
discontinuation. The model utilized data for treatment effects (estimated via net-
work meta-analyses), risks, mortality, quality of life (QoL – using EQ5D estimates) 
and costs, which were identified from a literature review. The main outcome was 
cost per QALY. Results: Results showed that CE/BZA lead to a gain in QALYs but 
was associated with higher total costs, resulting in a cost per QALY of $12,949 and 
$26,066 when compared with CE/MPA and no treatment, respectively. Driven by 
fewer bleeding events, women on CE/BZA received treatment for a longer duration 
than women receiving CE/MPA. The LTEs impacted results modestly. Uncertainty 
analyses indicated that results were robust to changes in key assumptions and input 
data, however results were most sensitive to changes in QoL associated with VMS 
and vaginal bleeding. ConClusions: CE/BZA is considered cost-effective for the 
treatment of VMS in postmenopausal women when compared with either CE/MPA 
or no treatment in the United States.
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objeCtives: Corifollitropin alfa, a fusion protein, has a longer elimination half-life 
and extended time to peak levels than recombinant FSH (rFSH). The main aim of this 
study was to perform comparative pharmacoeconomic analysis of using korifol-
litropin alfa with ganirelix and follitropin alfa with cetrorelix for ovarian stimula-
tion. Methods: Analysis of the published clinical trials was conducted to evaluate 
comparative efficacy and safety of the studied therapy options. Direct medical costs 
included drug therapy and hospital treatment. Taking into account the hypothesis 
of equal effectiveness of using korifollitropin alfa with ganirelix and follitropin 
alfa with cetrorelix for ovarian stimulation for pharmacoeconomic analysis was 
chosen “cost minimization” analysis (CMA). Direct medical costs were calculated 
for 1 patient. In this study were performed 2 variants of ovarian stimulation costs, 
in 1st variant was compared only korifollitropin alfa with ganirelix and follitropin 
alfa with cetrorelix, in 2ndvariant - korifollitropin alfa plus follitropin beta with 
ganirelix and follitropin alfa with cetrorelix. Results: According to published trials 
corifollitropin alfa was a novel and effective treatment option for potential normal 
responder patients undergoing ovarian stimulation with gonadotropin co-treatment 
resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. 
The average cost for 1st variant of a course of korifollitropin alfa with ganirelix was 
34 285 rubles ($ 640), and follitropin alfa with cetrorelix – 65 352 rubles ($ 1 220). The 
average cost for 2nd variant of a course of korifollitropin alfa plus follitropin beta 
with ganirelix was 66 886 rubles ($ 1 249), and follitropin alfa with cetrorelix – 65 
352 rubles ($ 1 220). The CMA has shown that annual savings when used for ovarian 
stimulation 1stvariant without follitropin beta will be 18%. ConClusions: The 
using for ovarian stimulation korifollitropin alfa with ganirelix was more economi-
cally justified treatment option.
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objeCtives: To examine the economic burden and health care utilization of 
menopausal women in the U.S. Medicaid population. Methods: Female patients 
diagnosed with menopausal symptoms and/or those prescribed estrogen hormone 
therapy were identified using the U.S. Medicaid database from 01JUL2008 through 
30JUN2010. The first diagnosis or prescription date was designated as the index date. 
Control patients were identified during the same time period and assigned a ran-
dom index date. Patients in both cohorts were required to be aged 40-65 years and 
have continuous, fee-for-service medical and pharmacy benefits, 6 months pre- and 
post-index date. Controls were matched to cases based on age, state, race and index 
study year. Health care resource utilization and costs during the 6-month follow-up 
period were compared between the menopause and control cohorts. Generalized 
linear models were used to adjust for differences in baseline and demographic char-
acteristics between the cohorts. Results: A total of 71,076 patients were included 
in each cohort. Patients in the menopause cohort were significantly more likely to 
be diagnosed with depression (23.4% vs. 17.3%, p< 0.001) and anxiety (11.6% vs. 8.0%, 
p< 0.001) compared to those in the control cohort. After adjusting for baseline and 
demographic characteristics, significantly more patients in the Menopause Cohort 
had inpatient (10.9% vs. 9.3%, p< 0.001), outpatient hospital (80.6% vs. 34.7%, p< 0.001) 
and physician office visits (89.7% vs. 74.8%, p< 0.001). Higher health care utilizations 
translated to higher health care costs for menopausal patients ($7,237 vs. $6,739, 
p< 0.001) compared to control patients. ConClusions: Patients diagnosed with 
menopausal symptoms or treated with hormone therapy incurred significantly 
higher health care utilization and costs compared to women without menopausal 
symptoms or treatment.
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costs. Results: Nexplanon was dominant in the base case and in the majority 
of sensitivity analyses. Nexplanon® allows to avoid 1.6 ‰ pregnancy per year 
over hormonal IUD, 7.3 ‰ over copper IUD and more than 24.7 ‰ over COC with 
savings of 115€ over hormonal IUD, 58€ over copper IUD and more than 868€ 
over COC. At a threshold of 10,000€ per unintended pregnancy avoided, Monte 
Carlo simulations demonstrated an 82.0% probability for Nexplanon® to be the 
most cost-effective method. An alternative analysis was proposed evaluating the 
cost per abortion avoided. In this analysis, the ICER of Nexplanon® versus cop-
per IUD was 8,896€ per abortion avoided while all other methods were strictly 
dominated. ConClusions: Nexplanon® is the most cost-effective strategy when 
compared to other reimbursed contraceptive methods. Additionally, this analysis 
demonstrates that Long-Acting Reversible Contraception (LARC) is dramatically 
more efficient than oral contraception.
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objeCtives: Conduct disorders (CD) are common psychiatric disorders in children, 
and place a high burden on the individuals and society. Parenting programs are the 
gold standard for the treatment of CD but little is known about their possible longer-
term cost-effectiveness. The study evaluated the population cost-effectiveness of 
Triple P, the most widely researched parenting program, for the treatment of CD 
in children, from the health sector perspective. This study is part of a series of 
economic evaluations undertaken at the Centre for Research Excellence in Mental 
Health Systems Improvement in Australia. Methods: A population-based Markov 
model was developed to estimate the cost per disability adjusted life year (DALY) 
averted of Triple P compared with no intervention. The target population was a 
cohort of 5-9 year old children with CD in the 2013 Australian population followed 
through the age of 18 years. Multivariate probabilistic and univariate sensitivity 
analysis were conducted to incorporate uncertainty in the model parameters and 
investigate the impact of assumptions in the outcomes. Results: Triple P was eval-
uated in three formats: Group face-to-face, Self-directed (SD)+telephone assisted, 
and a mixed provision alternative of 50% Group+50% SD+telephone. Group face-
to-face had an incremental cost-effectiveness ratio (ICER) of AU$19 069 per DALY 
averted with a 0.998 probability of cost-effectiveness; SD+telephone had an ICER 
of AU$31 920 per DALY averted with a 0.931 probability of cost-effectiveness; and 
the mixed provision alternative had an ICER of AU$25 494 per DALY averted with a 
0.986 probability of cost-effectiveness. ConClusions: Triple P for the treatment of 
CD is good value for money and should be considered as part of the priority setting 
process in Australia. Group face-to-face Triple P is the most cost-effective option. The 
model will be used for economic evaluations of other interventions targeting CD.
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objeCtives: To estimate the cost-effectiveness of the original r-hFSH (Gonal-f) 
when compared with one biosimilar (Bemfola) using the evidence from a head-to-
head registration trial. Methods: An Excel-based decision-tree model was devel-
oped depicting the different relevant outcomes that result from fertility treatment 
with r-hFSH. Probabilities were populated using the data from a head-to-head trial 
used by the biosimilar for its registration at EMA, using as relevant outcome the 
take-away baby rates found in the trial. Costs were populated from Portuguese 
official sources and include the cost of the two drugs, as well as the costs related 
with treatment, such as costs for IVF, ICSI, child delivery and abortion. The analy-
sis was performed from a societal perspective including only direct medical costs 
with no discounting since all costs occur in a single year. Results: According to 
the model, treatment of 1.000 women with Gonal-f will result in a total number of 
447 pregnancies, with 407 women achieving a new-born child. Total cost for this 
will be 3.062.802,80 € , for a cost per woman achieving a new-born child of 7.534,49 
€ . Respective values for the biossimilar are 361 pregnancies and 321 women with 
new-born children. Total cost for this alternative is 2.957.530,12 € , resulting in a 
cost per new-born child of 9.205,31 € . Incremental cost-effectiveness ratio obtained 
for Gonal-f vs Bemfola is 1.235,32 € per woman with a new-born child. Sensitivity 
analysis did not change the hierarchy in the results except on extreme values. For 
cost-effectiveness ratios to be similar the biosimilar would need a 91% price reduc-
tion. ConClusions: The biossimilar is extendedly dominated by Gonal-f, with 
its cost-effectiveness ratio being higher than the one found for Gonal-f. Under the 
current scenario the use of the biossimilar is not a cost-effective alternative to the 
use of Gonal-f and thus should be avoided.
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objeCtives: To estimate the cost-effectiveness of conjugated estrogens/bazedox-
ifene (CE/BZA) compared with conjugated estrogens/medroxyprogesterone (CE/
MPA) or no treatment in a cohort of postmenopausal U.S. women exhibiting vaso-
motor symptoms (VMS), with an intact uterus and at least 12 months since their last 
menses. Methods: A Markov cohort model was developed to compare CE/BZA with 
CE/MPA or no treatment in terms of costs and Quality Adjusted Life Years (QALYs). 
The model considered VMS, vaginal bleeding, and eight long-term events (LTEs): Hip 
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from which only 32 were original research empirical studies (0.3 0/000). Most studies 
were cross-sectional (72%), with only (25%) being prospective. Patient reported out-
comes were the most frequent adherence measures (65%). The Big Five model was 
the most frequent personality explicative framework (71%), followed by self-efficacy 
and beliefs. Conscientiousness was identified as an important adherent personality 
predictor. Quality of studies ranged between 53% and 86% with an average value of 
67% (SD= 8.8%). ConClusions: Although adherence is a frequently studied topic, few 
studies consider personal traits as a forecasting factor of medication persistence. A 
new instrument considering Conscientiousness as behavior predictor is being devel-
oped, the CUMPLE-Q.
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objeCtives: Primary non-adherence (PNA) has been found to range from 1% 
to 57% with a mean and median of 16.4% and 15.0%, respectively. We abstracted 
patient-centered reasons for PNA and their prevalence from the peer-reviewed lit-
erature. Methods: A systematic review using PubMed was conducted. A backward 
search of each abstracted article was performed as well as a review of each abstracted 
article’s reference list. Patient-provided reasons for PNA were abstracted from each 
reviewed article Results: A total of 131 articles met search-term criteria, and 19 
contained patient-provided reasons for PNA. Eleven additional articles were identi-
fied from backward citation searches and/or review of the 19 article’s reference list 
for a total of 30 studies. Fifty unique reasons for PNA were abstracted. After qualita-
tive analysis, they were reduced to seven mutually-exclusive reasons. Prescription-
medication affordability was the most common reason for PNA (80% of studies), 
followed by lack of perceived need for the medication (67% of studies), perceived 
medication concerns (53% of studies), lack of perceived drug efficacy (33% of studies), 
forgetfulness (33% of studies), access barriers (33% of studies), and patient knowledge 
(27% of studies). ConClusions: PNA is common both. Few adherence interventions 
have been developed and evaluated for PNA. The first step in developing adherence 
interventions for PNA is to gain an understanding of patient-centered reasons for 
PNA. This review identified the seven foremost reasons for PNA from 30 published 
studies. These seven reasons were: prescription-medication affordability, lack of per-
ceived need for the medication, perceived medication concerns, lack of perceived drug 
efficacy, forgetfulness, access barriers, and patient knowledge. Researchers should 
standardize the content of PNA reasons to facilitate comparisons across patient sam-
ples. Many of the reasons for PNA can be addressed with patient-centered counselling 
at the time of prescribing. If we are to reduce PNA, doctor-patient communication 
must be improved to address patients beliefs about the need for the medication and 
their concerns about it.
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objeCtives: Adherence measurements developed for mono-pharmacotherapy, 
such as the Medication Possession Ratio (MPR), are not appropriate to calculate 
adherence to poly-pharmacotherapy. These standard metrics tend to over/under 
estimate adherence in patients with treatment regimens consist of multiple medi-
cations. This study aimed to develop a new method for calculating medication 
adherence in patients using poly-pharmacotherapy by linking prescribing and 
administration data of general practitioners (GPs), and pharmacy dispensing 
records. Methods: We evaluated existing methods for calculating medication 
adherence from dispensing data records. Standards for estimating medication 
adherence to poly-pharmacotherapy were defined. A new approach to calculate 
adherence to poly-pharmacotherapy was developed. Results: The proposed 
new approach for estimating medication adherence to poly-pharmacotherapy 
consists 2 novel indexes (the multiple-Medications Prescribing Ratio [mMPrR] and 
the multiple-Medications Possession Ratio [mMPR]) and a medication adherence 
visualization tool (the Prescription and Medication Possession Graph [PMPG]). The 
mMPrP is for calculating adherence to prescribe medications and the mMPR to (re)fill 
prescriptions. The PMPG completes the mMPrR and the mMPR with indicating medi-
cation adherence in time and allowing to evaluate tendencies in the observation 
period. Among other parameters, number of medications, therapeutic indication, 
treatment length (e.g., chronic conditions requiring periodic treatment), dosage, 
generic and therapeutic switching, therapeutic duplication, and oversupply were 
considered for the construction of mMPrP, mMPR and PMPG. The face-validity of 
the approach were demonstrated with four illustrative cases (i.e., generic switch-
ing, therapeutic duplication, oversupply, periodic treatment). ConClusions: The 
proposed new method enables a more accurate measurement of adherence to poly-
pharmacotherapy compared to MPR. The mMPrP, the mMPR and the PMPG would 
allow GPs to identify substantial adherence issues during consultations and could 
be routinely used to enhance medication adherence in countries where GPs have 
access to pharmacy dispensing records of their patients such as in Hungary.
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objeCtives: Self-care with non-steroidal anti-inflammatory drugs (NSAIDs), etc. 
is widely used for pelvic pain relief in dysmenorrhea patients in Japan; however, 
guideline-recommended medical intervention consists of low-dose estrogen and 
progestin hormonal combinations (LEP). This study aims to assess the cost-effec-
tiveness of intervention including LEP for the prevention of endometriosis and/or 
disease progression of dysmenorrhea, compared to self-care, in Japan. Methods: 
A Markov model with a 43-year time horizon and annual cycles was constructed. 
The model consisted of five major health states with four sub-medical states based 
on gynecologists’ consensus. The analyses were conducted from social, payer’s and 
woman’s perspectives. Transition probabilities among health and medical states were 
derived from epidemiological patient surveys. Disease-associated direct costs, such as 
inpatient, outpatient, surgery, and prescription and over-the-counter (OTC) drug costs 
were included. Utility measures were collected prospectively from patients with stage 
I-IV endometriosis using a visual analogue scale. An annual discount rate at 3% was 
considered. Sensitivity analyses were performed to examine the impact of uncertain-
ties. Results: Base case outcomes indicated that intervention would be superior to 
self-care when only considering direct costs (cost-saving amount of approximately 
240,000 JPY, with 4.4 incremental quality-adjusted life-years [QALYs] gained). From 
the payer’s perspective, intervention would be more cost-effective than self-care, as 
the incremental cost-effectiveness ratio (ICER) yielded 350,000 JPY per QALY gained. 
A tornado diagram depicting the deterministic sensitivity analysis was constructed, 
and robustness of the base case was confirmed. A probabilistic analysis resulting from 
10,000-time Monte Carlo simulations demonstrated efficiency at Willingness-To-Pay 
thresholds of 5,000,000 JPY in more than 90% of the population. ConClusions: Our 
analysis demonstrated that, in Japan, intervention would be more cost-effective than 
self-care in preventing endometriosis and/or disease progression for patients with 
dysmenorrhea. These findings could be used to inform health-care decision-making 
in women with dysmenorrhea and health-policy makers.
IndIvIdUal’s HealTH – Patient-reported outcomes & Patient Preference  
studies
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objeCtives: This study reviews adherence metrics for Phase IV studies. Methods: 
We conducted a review of adherence metrics in the public domain. We critically 
appraised these metrics for use in Phase IV studies. Results: We identified 70 
unique self-report measures of adherence. One quarter (26%) were generic and the 
remaining were disease specific. Instrument length ranged from one to 78 items. 
One third (34%) only measured adherence behaviors, 37% only measured beliefs and 
attitudes, and 29% measured both. Just over one quarter (29%) were developed using 
a conceptual framework. One-fifth (21%) involved qualitative patient input during 
item generation or pretesting. Just over one-half (57%) had evidence of internal-
consistency reliability, and far fewer had evidence of test-retest reliability (23%). 
One half (50%) had evidence of validity vis á vis other self-report measures, 23% vis 
á vis other adherence metrics, and 19% vis á vis clinical criteria. Few had evidence 
of predictive (24%) or postdictive (13%) validity. ConClusions: Few adherence 
measures have been developed with true patient-centerednesss. There has been no 
standardization of the content of adherence behaviors or beliefs. Instrument vali-
dation has been inconsistent in its breadth and depth. Because of the importance 
of medication adherence to payers, providers, pharmacies, and pharmaceutical 
companies, the time seems opportune to conceptualize, develop, and validate a 
generic adherence measure that can be used in Phase IV studies across different 
disease and patient groups. Standardization of content would allow for the assess-
ment of adherence behaviors and beliefs between and across existing and novel 
therapies. There should be a minimum set of adherence concepts that apply across 
therapeutic areas. The new measure should be developed with patient input (con-
cept elicitation) and verified as to its comprehension and relevance using cognitive 
debriefing. The scientific basis of medication adherence would be advanced through 
the development and validation of a standardized generic measure that assesses 
adherence behaviors and beliefs.
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objeCtives: A systematic review of scientific articles was accomplished in order to 
identify personal factors used as predictors of adherence to medication. Methods: 
PubMed, PsycINFO, and cross-references were consulted using standardized queries. 
Original works were summarized using a pre-stablished set of content indicators. A 
multi-criteria decision analysis tool was developed to assess research quality, using 
12 independent criteria: Explicative model, adherence measure, predictive validity, 
pathologies studied, concurrent validity, structural validity, construct validity, dis-
criminant validity, sample size, study type, theoretical framework, and bibliographic 
review. Each criteria was valued as very good (100), good (80), acceptable (60), and 
bad (0/20); and a weighted sum was obtained considering all criteria. Valuations 
were carried out by two independent researchers and lack of agreement was dis-
entangled by a third reviewer. Results: A total of 113,560 studies were identified 
related to “adherence” and “persistence” between 1980 (454 studies) and May 2015, 
exhibiting an exponential growth rate with a maximum of 8,744 studies in 2014. 
After refining our search for personal predictive factors we ended with 272 articles 
